BG Medicine Posts 62 Percent Jump in Q2 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine today reported second quarter revenues of $1 million, up 62 percent from $622,000 in the second quarter of 2012.

The revenue increase was driven by $972,000 in revenues from sales of the company's BGM Galectin-3 test, a 72 percent jump from the $566,000 it posted in Q2 2012. The remaining $34,000 in revenues came from BG's services business, down 39 percent from $56,000 a year ago.

The company's revenues fell short of the average Wall Street estimate of $1.27 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."